NCT00002366已完成2 期
A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Abbott
- 试验地点
- 2
研究概览
简要总结
To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19COVID-19NCT04960202Pfizer2,091
已完成
2 期
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IIChronic Hepatitis CNCT03020004Ascletis Pharmaceuticals Co., Ltd.70
已完成
2 期
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddCHIV InfectionsNCT00001040Hoffmann-La Roche300
已完成
1 期
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and ChildrenHIV InfectionsNCT00000952National Institute of Allergy and Infectious Diseases (NIAID)60
已完成
2 期
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCOVID-19NCT05567952Pfizer436